Literature DB >> 19775255

Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition.

Osvaldo Martinez1, Joshua Johnson, Balaji Manicassamy, Lijun Rong, Gene G Olinger, Lisa E Hensley, Christopher F Basler.   

Abstract

Cathepsins B and L contribute to Ebola virus (EBOV) entry into Vero cells and mouse embryonic fibroblasts. However, the role of cathepsins in EBOV-infection of human dendritic cells (DCs), important targets of infection in vivo, remains undefined. Here, EBOV-like particles containing a beta-lactamase-VP40 fusion reporter and Ebola virus were used to demonstrate the cathepsin dependence of EBOV entry into human monocyte-derived DCs. However, while DC infection is blocked by cathepsin B inhibitor, it is insensitive to cathepsin L inhibitor. Furthermore, DCs pre-treated for 48 h with TNFalpha were generally less susceptible to entry and infection by EBOV. This decrease in infection was associated with a decrease in cathepsin B activity. Thus, cathepsin L plays a minimal, if any, role in EBOV infection in human DCs. The inflammatory cytokine TNFalpha modulates cathepsin B activity and affects EBOV entry into and infection of human DCs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19775255      PMCID: PMC2996272          DOI: 10.1111/j.1462-5822.2009.01385.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  39 in total

1.  Functional importance of the coiled-coil of the Ebola virus glycoprotein.

Authors:  S Watanabe; A Takada; T Watanabe; H Ito; H Kida; Y Kawaoka
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Ebola virus VP40-induced particle formation and association with the lipid bilayer.

Authors:  L D Jasenosky; G Neumann; I Lukashevich; Y Kawaoka
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4.

Authors:  Jillian M Licata; Martha Simpson-Holley; Nathan T Wright; Ziying Han; Jason Paragas; Ronald N Harty
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

4.  A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes.

Authors:  Marielle Cavrois; Carlos De Noronha; Warner C Greene
Journal:  Nat Biotechnol       Date:  2002-09-30       Impact factor: 54.908

5.  Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses.

Authors:  S Y Chan; R F Speck; M C Ma; M A Goldsmith
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Cathepsin S regulates the expression of cathepsin L and the turnover of gamma-interferon-inducible lysosomal thiol reductase in B lymphocytes.

Authors:  K Honey; M Duff; C Beers; W H Brissette; E A Elliott; C Peters; M Maric; P Cresswell; A Rudensky
Journal:  J Biol Chem       Date:  2001-04-16       Impact factor: 5.157

7.  Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses.

Authors:  Siddhartha Mahanty; Karen Hutchinson; Sudhanshu Agarwal; Michael McRae; Pierre E Rollin; Bali Pulendran
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

8.  Vesicular release of ebola virus matrix protein VP40.

Authors:  J Timmins; S Scianimanico; G Schoehn; W Weissenhorn
Journal:  Virology       Date:  2001-04-25       Impact factor: 3.616

9.  Nedd4 regulates egress of Ebola virus-like particles from host cells.

Authors:  Jiro Yasuda; Mitsuyoshi Nakao; Yoshihiro Kawaoka; Hisatoshi Shida
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen presentation by dendritic cells.

Authors:  E Fiebiger; P Meraner; E Weber; I F Fang; G Stingl; H Ploegh; D Maurer
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

View more
  36 in total

1.  Identification of a small-molecule entry inhibitor for filoviruses.

Authors:  Arnab Basu; Bing Li; Debra M Mills; Rekha G Panchal; Steven C Cardinale; Michelle M Butler; Norton P Peet; Helena Majgier-Baranowska; John D Williams; Ishan Patel; Donald T Moir; Sina Bavari; Ranjit Ray; Michael R Farzan; Lijun Rong; Terry L Bowlin
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment.

Authors:  Yasuteru Sakurai; Andrey A Kolokoltsov; Cheng-Chang Chen; Michael W Tidwell; William E Bauta; Norbert Klugbauer; Christian Grimm; Christian Wahl-Schott; Martin Biel; Robert A Davey
Journal:  Science       Date:  2015-02-27       Impact factor: 47.728

3.  Structural basis for Marburg virus neutralization by a cross-reactive human antibody.

Authors:  Takao Hashiguchi; Marnie L Fusco; Zachary A Bornholdt; Jeffrey E Lee; Andrew I Flyak; Rei Matsuoka; Daisuke Kohda; Yusuke Yanagi; Michal Hammel; James E Crowe; Erica Ollmann Saphire
Journal:  Cell       Date:  2015-02-26       Impact factor: 41.582

4.  Activation of the Nipah virus fusion protein in MDCK cells is mediated by cathepsin B within the endosome-recycling compartment.

Authors:  Sandra Diederich; Lucie Sauerhering; Michael Weis; Hermann Altmeppen; Norbert Schaschke; Thomas Reinheckel; Stephanie Erbar; Andrea Maisner
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

5.  A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry.

Authors:  Anthony C Wong; Rohini G Sandesara; Nirupama Mulherkar; Sean P Whelan; Kartik Chandran
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

6.  Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells.

Authors:  Lawrence W Leung; Man-Seong Park; Osvaldo Martinez; Charalampos Valmas; Carolina B López; Christopher F Basler
Journal:  Immunol Cell Biol       Date:  2011-01-25       Impact factor: 5.126

7.  Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.

Authors:  Irina N Gaisina; Norton P Peet; Letitia Wong; Adam M Schafer; Han Cheng; Manu Anantpadma; Robert A Davey; Gregory R J Thatcher; Lijun Rong
Journal:  J Med Chem       Date:  2020-06-17       Impact factor: 7.446

8.  Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles.

Authors:  Osvaldo Martinez; Lee Tantral; Nirupama Mulherkar; Kartik Chandran; Christopher F Basler
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

9.  Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells.

Authors:  Joshua C Johnson; Osvaldo Martinez; Anna N Honko; Lisa E Hensley; Gene G Olinger; Christopher F Basler
Journal:  Antiviral Res       Date:  2014-05-09       Impact factor: 5.970

10.  Ebola virus exploits a monocyte differentiation program to promote its entry.

Authors:  Osvaldo Martinez; Joshua C Johnson; Anna Honko; Benjamin Yen; Reed S Shabman; Lisa E Hensley; Gene G Olinger; Christopher F Basler
Journal:  J Virol       Date:  2013-01-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.